Acorda/Biogen Idec's Ampyra becomes first US FDA-approved drug to improve walking in MS
This article was originally published in Scrip
The US FDA has approved Acorda Therapeutics/Biogen Idec's oral drug Ampyra (dalfampridine; formerly fampridine SR) to improve walking in patients with multiple sclerosis, making it the first drug to be approved for the management of specific symptoms of the disease.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.